Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17092626 | 0.88 | HRH1 (0.46) | HRH1SLC7A5TAAR1SLC6A2SLC6A4 | |
| SCHEMBL6642483 | 0.81 | SLC7A5 (0.43) | HRH1HTR2ASLC7A5TAAR1SLC6A2 | |
| SCHEMBL9879846 | 0.81 | TAAR1 (0.44) | HTR2ASLC7A5TAAR1SLC6A2SLC6A4 | |
| SCHEMBL28434383 | 0.80 | CES2 (0.34) | SLC7A5TAAR1 | |
| SCHEMBL14288464 | 0.77 | HDAC1 (0.39) | — | |
| SCHEMBL21381224 | 0.76 | SLC1A3 (0.43) | HRH1HTR2ASLC7A5TAAR1ALOX5 | |
| SCHEMBL14796046 | 0.75 | CES2 (0.36) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5684870 | 0.72 | NPC1 (0.51) | SLC7A5TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL604916 | 0.72 | TAAR1 (0.58) | HRH1HTR2ATAAR1SLC6A2SLC6A4 | |
| SCHEMBL1201233 | 0.72 | NPC1 (0.51) | SLC7A5TAAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018227-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY | THE JOHNS HOPKINS UNIVERSITY | 2024-01-18 | — | — | US | disclosed |
| WO-2022093967-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3965820-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | The Regents of the University of California (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020226683-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-12 | — | — | WO | disclosed |
| US-8519154-B2 | Method for treatment of bronchial asthma | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-08-27 | — | — | US | disclosed |
| EP-2585068-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| US-20120202868-A1 | METHOD FOR TREATMENT OF BRONCHIAL ASTHMA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-09 | — | — | US | disclosed |
| EP-2271332-B1 | USE OF COMPOUNDS IN THE TREATMENT OF TAUOPATHY | BIOALVO SERVICOS INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA S A (PT) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2005087213-A1 | COMBINATION OF DERAMCICLANE AND OPOIDS AS ANALGESICS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-09-22 | — | — | WO | disclosed |
| US-6063803-A | ANALGESICS AND CHEMICAL INTERMEDIATES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999065911-A1 | OCTAHYDROPYRROLO-[3,4-c]CARBAZOLES USEFUL AS ANALGESIC AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5837716-A | ANALGESICS | ALBANY MEDICAL COLLEGE (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0861075-A1 | ANALGESIC COMPOUNDS AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997017954-A1 | ANALGESIC COMPOUNDS AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5534517-A | (Aryl(alkyl)carbonyl)-heterocyclic compounds and their use in the treatment of anxiety and depression | ADIR ET COMPAGNIE (FR) | 1996-07-09 | — | — | US | disclosed |
| EP-0657455-A1 | Epi-epibatidine derivatives, a process and intermediates for preparing them and epi-epibatidine and medicaments containing the epi-epibatidine derivatives and/or epi-epibatidine and the use of them | EGIS GYOGYSZERGYAR (HU) | 1995-06-14 | — | — | EP | disclosed |
| US-5387586-A | Analgesics, nervous system disorders | ADIR ET COMPAGNIE (FR) | 1995-02-07 | — | — | US | disclosed |
| EP-0613898-A1 | Aryl or arylalkyl-carbonyl heterocyclic derivatives, processes for their preparation and compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202868-A1 | METHOD FOR TREATMENT OF BRONCHIAL ASTHMA | CHRM3, CHRM1, CHRM2 | HRH1 18/4885HTR2A 3819/4885SLC7A5 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.